The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: A pilot study

Sivoňová,Monika   Kmeťová; Vilčková,Marta; Jurečeková,Jana; Hatok,Jozef; Dobrota,Dušan; Dušenka,Róbert; Kliment,Ján

doi:10.3892/mmr.2012.1242

The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: A pilot study

Authors:
- Monika Kmeťová Sivoňová
- Marta Vilčková
- Jana Jurečeková
- Jozef Hatok
- Dušan Dobrota
- Róbert Dušenka
- Ján Kliment
View Affiliations

Affiliations: Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic, Department of Urology, Comenius University in Bratislava, Jessenius Faculty of Medicine and University Hospital of Martin, Martin, Slovak Republic
Published online on: December 18, 2012 https://doi.org/10.3892/mmr.2012.1242
Pages: 986-990

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cell cycle regulator p21 plays an important role in regulating critical cell activities including cell cycle control, DNA repair and apoptosis. Consequently, it may affect the efficacy of the response to DNA damage and tumor development. The aim of our study was to evaluate the frequencies of the p21 C70T polymorphism, the association between this genetic variant and smoking status, and the serum prostate-specific antigen (PSA) levels and Gleason score in 118 prostate cancer patients and 130 males routinely screened for prostate cancer in the Slovak population. Blood samples were collected from all individuals for DNA isolation, used for subsequent genotyping assays via PCR-RFLP methods. Overall, we did not observe any significant association between this polymorphism and prostate cancer risk. An analysis of the association between the p21 genotypes and smoking was then conducted. Among smokers, CC and CT genotypes were associated with a non‑significant increased risk (OR=1.48; 95% CI, 0.80-2.76 and OR=1.15; 95% CI, 0.27‑4.77, respectively; p>0.05) in comparison to non-smokers with the CC genotype. Patients with a CT genotype and serum PSA levels ≥10 ng/ml had an 84% decrease in prostate cancer risk (OR=0.16; 95% CI, 0.03-0.75; p<0.05) compared to cases with serum PSA levels <10 ng/ml and the CC genotype. No significant association was detected between Gleason score and prostate cancer risk. Based on these results, we concluded that the p21 C70T polymorphism is associated with decreased risk of prostate cancer in Slovak men. To confirm these findings, a systematic approach is required to identify sequence variants in this and other related genes, and subsequently, to test for an association between such variants, smoking status and tumor-specific clinicopathological characteristics in large samples.

View Figures

View References

1	Grönberg H: Prostate cancer epidemiology. Lancet. 361:859–864. 2003.PubMed/NCBI
2	Sivonova MK, Dobrota D, Matakova T, et al: Microsomal epoxide hydrolase polymorphisms, cigarette smoking and prostate cancer risk in the Slovak population. Neoplasma. 59:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
3	Khan N, Adhami VM and Mukhtar H: Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 17:39–52. 2010. View Article : Google Scholar
4	Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 1:639–649. 2002.PubMed/NCBI
5	Liu S, Bishop WR and Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
6	Suzuki H, Ito R, Ikeda K and Tamura TA: TATA-binding protein (TBP)-like protein is required for p53-dependent transcriptional activation of an upstream promoter of the p21Waf1/Cip1 gene. J Biol Chem. 282:19792–19803. 2012. View Article : Google Scholar : PubMed/NCBI
7	Englert C, Maheswaran S, Garvin AJ, Kreidberg J and Haber DA: Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 57:1429–1434. 1997.
8	Deng C, Zhang P, Harper JW, Elledge SJ and Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:675–684. 1995. View Article : Google Scholar : PubMed/NCBI
9	Gartel AL: The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res. 29:1237–1238. 2005. View Article : Google Scholar : PubMed/NCBI
10	El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
11	Ma H, Zhou Z, Wei S and Wei Q: Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis. Chin J Cancer. 30:254–263. 2011. View Article : Google Scholar : PubMed/NCBI
12	Gravina S, Lescai F, Hurteau G, et al: Identification of single nucleotide polymorphisms in the p21 (CDKN1A) gene and correlations with longevity in the Italian population. Aging (Albany NY). 1:470–480. 2009.PubMed/NCBI
13	Keshava C, Frye BL, Wolff MS, McCanlies EC and Weston A: Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 11:127–130. 2002.PubMed/NCBI
14	Liu F, Li B, Wei Y, et al: P21 codon 31 polymorphism associated with cancer among white people: evidence from a meta-analysis involving 78,074 subjects. Mutagenesis. 26:513–521. 2011. View Article : Google Scholar : PubMed/NCBI
15	Li G, Liu Z, Sturgis EM, et al: Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 26:1596–1602. 2005. View Article : Google Scholar : PubMed/NCBI
16	Taghavi N, Biramijamal F, Abbaszadegan MR, Khademi H, Sotoudeh M and Khoshbakht S: P21(waf1/cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: a preliminary study. Arch Iran Med. 13:235–242. 2010.PubMed/NCBI
17	Lin G, Fang F, Yu XJ and Yu L: Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility. Genet Mol Res. 10:2449–2456. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shirai O, Ohmiya N, Taguchi A, et al: P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology. 57:1595–1601. 2010.PubMed/NCBI
19	Ebner F, Schremmer-Danninger E and Rehbock J: The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. J Cancer Res Clin Oncol. 136:1369–1375. 2010. View Article : Google Scholar : PubMed/NCBI
20	Yang W, Qi Q, Zhang H, et al: p21 Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann Surg Oncol. 17:1453–1458. 2010. View Article : Google Scholar : PubMed/NCBI
21	Huang SP, Wu WJ, Chang WS, et al: p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 13:2217–2224. 2004.PubMed/NCBI
22	Facher EA, Becich MJ, Deka A and Law JC: Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 79:2424–2429. 1997. View Article : Google Scholar : PubMed/NCBI
23	Gao X, Chen YQ, Wu N, et al: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene. 11:1395–1398. 1995.PubMed/NCBI
24	Kibel AS, Suarez BK, Belani J, et al: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63:2033–2036. 2003.PubMed/NCBI
25	Wang Z, Sturgis EM, Zhang F, et al: Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. Mol Cancer. 11:172012. View Article : Google Scholar : PubMed/NCBI
26	Rastinejad F and Blau HM: Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell. 72:903–917. 1993.
27	Valentin MD, Canalle R, Queiroz Rde P and Tone LG: Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors. Sao Paulo Med J. 127:288–294. 2009. View Article : Google Scholar : PubMed/NCBI
28	Sivonová M, Waczulíková I, Dobrota D, et al: Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer: a case-control study. J Exp Clin Cancer Res. 28:322009.PubMed/NCBI
29	Lei D, Sturgis EM, Liu Z, Zafereo ME, Wei Q and Li G: Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis. 31:222–227. 2010. View Article : Google Scholar : PubMed/NCBI
30	Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M and Kosma VM: Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate. 39:8–15. 1993. View Article : Google Scholar : PubMed/NCBI
31	Baretton GB, Klenk U, Diebold J, Schmeller N and Lohrs U: Proliferation and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer. 80:546–555. 1999. View Article : Google Scholar
32	Omar EA, Behlouli H, Chevalier S and Aprikian AG: Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate. 49:191–199. 2001. View Article : Google Scholar : PubMed/NCBI